The “patent death squad” label has haunted PTAB since 2012. The actual data tells a different story — one where […]

Combination drugs — pairing a biologic with a small molecule — are among the most commercially valuable assets in pharma.

The global generic drug market will cross $700 billion by 2032. Most of that growth will not come from the

Generic drugs fill 90% of U.S. prescriptions and capture 18% of revenue. That gap is the whole game. The companies

A technical and commercial intelligence guide to complex generic development, patent strategy, regulatory sequencing, and emerging market positioning for pharma

The generic drug industry operates on a paradox that never fully resolves. Generic and biosimilar medicines fill 90% of all

Forty years after Congress passed the Drug Price Competition and Patent Term Restoration Act of 1984, the law’s core tension

The Orange Book and Purple Book are not regulatory housekeeping. They are the official ledgers where billions of dollars of

More than $200 billion in pharmaceutical revenue faces patent expiry through 2030, with some analyst projections reaching $300 billion. For